Squamous cell carcinoma of the head and neck (HNSCC) is the 6th most common cancer worldwide. It accounts for 600.000 new cases and 350.000 deaths every year. HNSCC can be subdivided into two distinct subgroups: HPV-positive and HPV-negative. They present very different features including etiological agent, age, socioeconomic status, prognosis, genetic landscape, and tissue differentiation. Nevertheless, all HNSCC patients are treated with the same therapies, comprising chemo- and radiotherapy, and/or surgery. Specific therapies for HPV-positive HNSCC are needed. HPV oncoproteins E6/E7 are the drivers of oncogenesis in HPV-related cancers and they can be used as targets for therapy. To this end, we studied the effects of the knock down of E6/E7 in HNSCC-positive cell lines and we looked for pharmacological treatments to downregulate E6/E7 levels. We found that targeting the EGFR/ERK/FOS signaling pathway induced a transcriptional reduction of E6/E7 and that the ERK inhibitor Ravoxertinib was effective in killing HPV-positive HNSCC cell lines. Thus, this is a potential novel approach to address HPV+ HNSCC cancer.

TARGETING EGFR/ERK/FOS SIGNALING AS A NOVEL APPROACH FOR HPV-POSITIVE HEAD AND NECK CANCER TREATMENT / A. Medda ; tutor: S. Chiocca ; phd coordinator: G. Viale. - : . Dipartimento di Oncologia ed Emato-Oncologia, 2021 Mar 30. ((32. ciclo, Anno Accademico 2020. [10.13130/medda-alessandro_phd2021-03-30].

TARGETING EGFR/ERK/FOS SIGNALING AS A NOVEL APPROACH FOR HPV-POSITIVE HEAD AND NECK CANCER TREATMENT

A. Medda
2021

Abstract

Squamous cell carcinoma of the head and neck (HNSCC) is the 6th most common cancer worldwide. It accounts for 600.000 new cases and 350.000 deaths every year. HNSCC can be subdivided into two distinct subgroups: HPV-positive and HPV-negative. They present very different features including etiological agent, age, socioeconomic status, prognosis, genetic landscape, and tissue differentiation. Nevertheless, all HNSCC patients are treated with the same therapies, comprising chemo- and radiotherapy, and/or surgery. Specific therapies for HPV-positive HNSCC are needed. HPV oncoproteins E6/E7 are the drivers of oncogenesis in HPV-related cancers and they can be used as targets for therapy. To this end, we studied the effects of the knock down of E6/E7 in HNSCC-positive cell lines and we looked for pharmacological treatments to downregulate E6/E7 levels. We found that targeting the EGFR/ERK/FOS signaling pathway induced a transcriptional reduction of E6/E7 and that the ERK inhibitor Ravoxertinib was effective in killing HPV-positive HNSCC cell lines. Thus, this is a potential novel approach to address HPV+ HNSCC cancer.
TESTA, GIUSEPPE
VIALE, GIUSEPPE
HPV; EGFR; PI3K/Akt/mTOR; AP-1; Head and Neck cancer
Settore BIO/11 - Biologia Molecolare
TARGETING EGFR/ERK/FOS SIGNALING AS A NOVEL APPROACH FOR HPV-POSITIVE HEAD AND NECK CANCER TREATMENT / A. Medda ; tutor: S. Chiocca ; phd coordinator: G. Viale. - : . Dipartimento di Oncologia ed Emato-Oncologia, 2021 Mar 30. ((32. ciclo, Anno Accademico 2020. [10.13130/medda-alessandro_phd2021-03-30].
Doctoral Thesis
File in questo prodotto:
File Dimensione Formato  
phd_unimi_R11753.pdf

accesso aperto

Descrizione: Tesi Dottorato
Tipologia: Tesi di dottorato completa
Dimensione 18.56 MB
Formato Adobe PDF
18.56 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/820693
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact